NRC Health (NRC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.44%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 8.44% | Share-based compensation / revenue. Period ending 2026-06-30. $11.81M ÷ $140.00M × 100 ≈ 8.44% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 140.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 11.81M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 14.74M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $140.00M | $11.81M | $14.74M | (m) | (m) | 8.44% | (m) | (m) |
| 2026-03-31 | (m) | $138.64M | $4.75M | $19.56M | (m) | (m) | 3.43% | (m) | (m) |
| 2025-12-31 | (m) | $137.39M | $3.31M | $22.59M | (m) | (m) | 2.41% | (m) | (m) |
| 2025-09-30 | (m) | $139.10M | $1.59M | $27.51M | $4.12M | (m) | 1.14% | 6.67× | Reported |
| 2025-06-30 | (m) | $140.31M | $855.00K | $27.75M | $3.37M | (m) | 0.61% | 8.24× | Reported |
| 2025-03-31 | (m) | $141.30M | $491.00K | $35.03M | $2.89M | (m) | 0.35% | 12.13× | Reported |
| 2024-12-31 | (m) | $143.06M | $284.00K | $35.19M | $2.60M | (m) | 0.20% | 13.56× | Reported |
| 2024-09-30 | (m) | $144.16M | $354.00K | $37.31M | (m) | (m) | 0.25% | (m) | (m) |
| 2024-06-30 | (m) | $146.28M | $233.00K | $39.29M | (m) | (m) | 0.16% | (m) | (m) |
| 2024-03-31 | (m) | $147.42M | $595.00K | $39.79M | $1.23M | (m) | 0.40% | 32.45× | Reported |
| 2023-12-31 | (m) | $148.58M | $935.00K | $40.05M | $862.00K | (m) | 0.63% | 46.46× | Reported |
| 2023-09-30 | (m) | $148.72M | $967.00K | $40.58M | $880.00K | (m) | 0.65% | 46.11× | Reported |
| 2023-06-30 | (m) | $148.47M | $1.19M | $41.73M | $1.01M | (m) | 0.80% | 41.44× | Reported |
| 2023-03-31 | (m) | $149.60M | $1.22M | $43.86M | $1.13M | (m) | 0.81% | 38.71× | Reported |
| 2022-12-31 | (m) | $151.57M | $1.20M | $46.54M | $1.21M | (m) | 0.79% | 38.50× | Reported |
| 2022-09-30 | (m) | $151.72M | $1.26M | $47.17M | $1.32M | (m) | 0.83% | 35.68× | Reported |
| 2022-06-30 | (m) | $151.80M | $1.09M | $49.20M | $1.45M | (m) | 0.72% | 34.00× | Reported |
| 2022-03-31 | (m) | $150.93M | $962.00K | $49.95M | $1.55M | (m) | 0.64% | 32.18× | Reported |
| 2021-12-31 | (m) | $147.95M | $623.00K | $50.27M | $1.67M | (m) | 0.42% | 30.16× | Reported |
| 2021-09-30 | (m) | $144.43M | $208.00K | $47.58M | $1.72M | (m) | 0.14% | 27.75× | Reported |
| 2021-06-30 | (m) | $140.14M | $356.00K | $46.47M | $1.75M | (m) | 0.25% | 26.49× | Reported |
| 2021-03-31 | (m) | $134.88M | $294.00K | $43.50M | $1.78M | (m) | 0.22% | 24.44× | Reported |
| 2020-12-31 | (m) | $133.28M | $680.00K | $42.68M | $1.81M | (m) | 0.51% | 23.54× | Reported |
| 2020-09-30 | (m) | $131.13M | $1.05M | $44.45M | $1.84M | (m) | 0.80% | 24.11× | Reported |
| 2020-06-30 | (m) | $130.11M | $1.09M | $42.65M | $1.90M | (m) | 0.84% | 22.42× | Reported |
| 2020-03-31 | (m) | $130.36M | $1.25M | $43.52M | $1.99M | (m) | 0.96% | 21.92× | Reported |
| 2019-12-31 | (m) | $127.98M | $1.22M | $43.03M | $2.09M | (m) | 0.96% | 20.58× | Reported |
| 2019-09-30 | (m) | (m) | $1.18M | $40.47M | $2.14M | (m) | (m) | 18.95× | Reported |
| 2019-06-30 | (m) | (m) | $1.13M | $39.41M | $2.17M | (m) | (m) | 18.17× | Reported |
| 2019-03-31 | (m) | (m) | $1.36M | $37.02M | $2.08M | (m) | (m) | 17.84× | Reported |
| 2018-12-31 | (m) | $119.69M | $1.51M | $35.27M | $1.51M | (m) | 1.26% | 23.31× | Reported |
| 2018-09-30 | (m) | (m) | $1.83M | $34.54M | $1.00M | (m) | (m) | 34.40× | Reported |
| 2018-06-30 | (m) | (m) | $2.05M | $32.50M | $479.00K | (m) | (m) | 67.84× | Reported |
| 2018-03-31 | (m) | (m) | $1.85M | $33.19M | $63.00K | (m) | (m) | 526.87× | Reported |
| 2017-12-31 | (m) | $117.56M | $1.84M | $34.22M | $82.00K | (m) | 1.57% | 417.30× | Reported |
| 2017-09-30 | (m) | $116.03M | $1.65M | $34.39M | $100.00K | (m) | 1.43% | 343.92× | Reported |
| 2017-06-30 | (m) | $114.11M | $1.64M | $34.61M | $119.00K | (m) | 1.44% | 290.83× | Reported |
| 2017-03-31 | (m) | $111.79M | $1.84M | $33.17M | $132.00K | (m) | 1.65% | 251.33× | Reported |
| 2016-12-31 | (m) | $109.38M | $1.93M | $31.20M | $190.00K | (m) | 1.76% | 164.19× | Reported |
| 2016-09-30 | (m) | $107.38M | $2.01M | $30.07M | $206.00K | (m) | 1.87% | 145.97× | Reported |
| 2016-06-30 | (m) | $105.59M | $1.91M | $29.28M | $221.00K | (m) | 1.81% | 132.48× | Reported |
| 2016-03-31 | (m) | $103.94M | $1.74M | $28.62M | $242.00K | (m) | 1.67% | 118.28× | Reported |
| 2015-12-31 | (m) | $102.34M | $1.38M | $26.45M | $220.00K | (m) | 1.35% | 120.21× | Reported |
| 2015-09-30 | (m) | $101.10M | $1.27M | $25.16M | $241.00K | (m) | 1.26% | 104.39× | Reported |
| 2015-06-30 | (m) | $99.54M | $1.17M | $25.77M | $265.00K | (m) | 1.17% | 97.25× | Reported |
| 2015-03-31 | (m) | $99.08M | $1.04M | $25.73M | $287.00K | (m) | 1.05% | 89.63× | Reported |
| 2014-12-31 | (m) | $98.84M | $742.00K | $28.30M | $305.00K | (m) | 0.75% | 92.77× | Reported |
| 2014-09-30 | (m) | $96.64M | $647.00K | $27.90M | $324.00K | (m) | 0.67% | 86.12× | Reported |
| 2014-06-30 | (m) | $95.36M | $628.00K | $26.77M | $340.00K | (m) | 0.66% | 78.75× | Reported |
| 2014-03-31 | (m) | $93.71M | $625.00K | $25.99M | $361.00K | (m) | 0.67% | 71.99× | Reported |
| 2013-12-31 | (m) | $92.59M | $955.00K | $24.81M | $397.00K | (m) | 1.03% | 62.48× | Reported |
| 2013-09-30 | (m) | $91.66M | $915.00K | $24.55M | $434.00K | (m) | 1.00% | 56.58× | Reported |
| 2013-06-30 | (m) | $90.64M | $763.00K | $24.17M | $476.00K | (m) | 0.84% | 50.78× | Reported |
| 2013-03-31 | (m) | $88.92M | $554.00K | $23.85M | $516.00K | (m) | 0.62% | 46.23× | Reported |
| 2012-12-31 | (m) | $86.42M | $388.00K | $22.72M | $541.00K | (m) | 0.45% | 41.99× | Reported |
| 2012-09-30 | (m) | $83.54M | $404.00K | $21.95M | $565.00K | (m) | 0.48% | 38.86× | Reported |
| 2012-06-30 | (m) | $80.70M | $347.00K | $20.50M | $585.00K | (m) | 0.43% | 35.05× | Reported |
| 2012-03-31 | (m) | $78.38M | $595.00K | $19.12M | $602.00K | (m) | 0.76% | 31.76× | Reported |
| 2011-12-31 | (m) | $75.77M | $763.00K | $18.73M | $629.00K | (m) | 1.01% | 29.79× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $63.40M | $779.00K | $13.86M | $491.00K | (m) | 1.23% | 28.22× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $57.69M | $619.00K | $13.70M | $405.00K | (m) | 1.07% | 33.82× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |